Proxy Results Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 20, 2024, Organovo Holdings, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders approved the amendment and restatement of the Organovo Holdings, Inc. 2022 Equity Incentive Plan (the "Amended and Restated Plan") to increase the number of shares reserved for issuance thereunder by 1,775,000 shares. The Amended and Restated Plan was previously approved by the Board of Directors of the Company (the "Board"), subject to stockholder approval.

The Amended and Restated Plan became effective immediately upon stockholder approval at the Annual Meeting. A more complete summary of the terms of the Amended and Restated Plan is set forth in "Proposal 4: Approval of Amendment and Restatement of the Organovo Holdings, Inc. 2022 Equity Incentive Plan to Increase the Number of Shares Reserved for Issuance Thereunder by 1,775,000 Shares" in the Company's definitive proxy statement filed with the Securities and Exchange Commission on October 7, 2024 (the "Proxy Statement"), which description and text are incorporated herein by reference.

The foregoing description of the terms of the Amended and Restated Plan and the description thereof incorporated by reference from the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the Amended and Restated Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.